Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

By afschroeder • February 17, 2026

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026 Feb 13:S1470-2045(25)00709-0. doi: 10.1016/S1470-2045(25)00709-0. Epub ahead of print. PMID: 41698381.

Tags: Hematology/Oncology, Publications

Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer

Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata[...]

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]